Lung cancer, particularly NSCLC, is the foremost reason behind deaths associated with cancer globally and the second most prevalent malignancy among males in Iraq. Mutations in the EGFR gene are significant druggable targets in NSCLC, linked to sensitivity to tyrosine kinase inhibitors. This study aims to analyse the incidence and kinds of EGFR mutations in Iraqi NSCLC patients and their correlation with gender and smoking status, despite global data indicating that EGFR mutations are more prevalent in females and non-smokers.
Materials and methods
A retrospective analysis was conducted on 214 FFPET samples. Information regarding the patients’ gender and smoking history was documented. DNA was extracted use the NucleoSpin tissue kit, and EGFR mutations were identified employing the Cobas z 480 analyser. The prevalence and types of mutations were associated with gender and smoking status; a p-value below 0.05 was regarded as statistically significant.
Results
Among 214 NSCLC cases, 51 (23.8%) exhibited EGFR mutations, with 58.8% being male and 41.2% female. The exon 19 deletion, Exdel19, represented the highest prevalence in both males and females, constituting 70% and 71.4%, respectively. The smoking status exhibited a significant correlation with Exdel19 mutation status (p = 0.048), indicating a considerably greater mutation rate among nonsmokers.
Conclusion
The results of this study demonstrated the influence of smoking on the occurrence of EGFR mutations, particularly Exdel19, in Iraqi lung cancer patients. Systematic evaluation of EGFR mutations, in conjunction with smoking reduction initiatives, will enhance results with targeted therapy and diminish the burden of lung cancer both locally and globally.
TorreLABrayFSiegelRL, et al.Global cancer statistics, 2012. CA Cancer J Clin2015; 65(2): 87–108.
2.
SiegelRLMillerKDJemalA. Cancer statistics, 2018. CA Cancer J Clin2018; 68(1): 7–30.
3.
Globocan. Cancer incidence and mortality in Iraq, WHO organization. Lyon: International Agency for Research on Cancer, 2021.
4.
GyobaJShanSRoaW, et al.Diagnosing lung cancers through examination of micro-RNA biomarkers in blood, plasma, serum and sputum: a review and summary of current literature. Int J Mol Sci2016; 17(4): 494.
5.
MorgenszternDNgSHGaoF, et al.Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol2010; 5(1): 29–33.
6.
KanodraNMSilvestriGATannerNT. Screening and early detection efforts in lung cancer. Cancer2015; 121(9): 1347–1356.
7.
ShigematsuHLinLTakahashiT, et al.Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst2005; 97(5): 339–346.
8.
LeighlNBRekhtmanNBiermannWA, et al.Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline. J Clin Oncol2014; 32(32): 3673–3679.
9.
LindemanNICaglePTBeasleyMB, et al.Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol2013; 8(7): 823–859.
10.
MinguetJSmithKHBramlageP. Targeted therapies for treatment of non‐small cell lung cancer—recent advances and future perspectives. Int J Cancer2016; 138(11): 2549–2561.
11.
WuY-LSaijoNThongprasertS, et al.Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC. Lung Cancer2017; 104: 119–125.
12.
HechtSS. Lung carcinogenesis by tobacco smoke. Int J Cancer2012; 131(12): 2724–2732.
13.
Buro-AuriemmaLJSalitJHackettNR, et al.Cigarette smoking induces small airway epithelial epigenetic changes with corresponding modulation of gene expression. Hum Mol Genet2013; 22(23): 4726–4738.
14.
WangT-HHsiaS-MShihY-H, et al.Association of smoking, alcohol use, and betel quid chewing with epigenetic aberrations in cancers. Int J Mol Sci2017; 18(6): 1210.
15.
IrfanR. Cigarette smoke induces distinct histone modifications in lung cells: Implications for the pathogenesis of COPD and lung cancer. J Proteome Res2014; 13: 982–996.
16.
LuLXuHYangP, et al.Involvement of HIF-1α-regulated miR-21, acting via the Akt/NF-κB pathway, in malignant transformation of HBE cells induced by cigarette smoke extract. Toxicol Lett2018; 289: 14–21.
17.
DuXQiFLuS, et al.Nicotine upregulates FGFR3 and RB1 expression and promotes non-small cell lung cancer cell proliferation and epithelial-to-mesenchymal transition via downregulation of miR-99b and miR-192. Biomed Pharmacother2018; 101: 656–662.
18.
WhitemanDCWilsonLF. The fractions of cancer attributable to modifiable factors: a global review. Cancer Epidemiol2016; 44: 203–221.
19.
WahbahMBoroumandNCastroC, et al.Changing trends in the distribution of the histologic types of lung cancer: a review of 4,439 cases. Ann Diagn Pathol2007; 11(2): 89–96.
20.
HsuK-HHoC-CHsiaT-C, et al.Identification of five driver gene mutations in patients with treatment-naive lung adenocarcinoma in Taiwan. PLoS One2015; 10(3): e0120852.
21.
TsengJ-SWangC-LYangT-Y, et al.Divergent epidermal growth factor receptor mutation patterns between smokers and non-smokers with lung adenocarcinoma. Lung Cancer2015; 90(3): 472–476.
22.
KawaguchiTTakadaMKuboA, et al.Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol2010; 5(5): 620–630.
23.
MetwallyYFElsaidAMElsaddaRR, et al.Impact of IL-6 and il-1β gene variants on non-small-cell lung cancer risk in Egyptian patients. Biochem Genet2024; 62(5): 3367–3388.
24.
ThandraKCBarsoukASaginalaK, et al.Epidemiology of lung cancer. Contemp Oncol2021; 25(1): 45–52.
25.
BaiuITitanALMartinLW, et al.The role of gender in non-small cell lung cancer: a narrative review. J Thorac Dis2021; 13(6): 3816–3826.
26.
CollissonECampbellJBrooksA, et al.Comprehensive molecular profiling of lung adenocarcinoma: The cancer genome atlas research network. Nature2014; 511(7511): 543–550.
ThongprasertSDuffieldESaijoN, et al.Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). J Thorac Oncol2011; 6(11): 1872–1880.
29.
ReckMHeigenerDFMokT, et al.Management of non-small-cell lung cancer: recent developments. Lancet2013; 382(9893): 709–719.
30.
RamadhanHHTaabanDFHassanJK. The frequency of epidermal growth factor receptor (EGFR) mutations in Iraqi patients with non-small cell lung cancer (NSCLC). Asian Pac J Cancer Prev APJCP2021; 22(2): 591–596.
31.
TanakaTMatsuokaMSutaniA, et al.Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer2010; 126(3): 651–655.
32.
Calibasi-KocalGAmirfallahASeverT, et al.EGFR mutation status in a series of Turkish non-small cell lung cancer patients. Biomed Rep2020; 13(2): 1.
33.
SowMLEl YacoubiHMoukafihB, et al.Frequency and types of EGFR mutations in Moroccan patients with non-small cell lung cancer. Tumori2021; 107(4): 335–340.
34.
LivshunSMatvieievaAKaminskyiD, et al.31P EGFR mutation rate and spectrum in Ukrainian patients with advanced NSCLC: Relation to gender and PD-L1 expression. J Thorac Oncol2023; 18(4): S58.
35.
LinardouHDahabrehIJBafaloukosD, et al.Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol2009; 6(6): 352–366.
36.
TarigopulaARamasubbanGChandrashekarV, et al.EGFR mutations and ROS1 and ALK rearrangements in a large series of non‐small cell lung cancer in South India. Cancer Rep2020; 3(6): e1288.
37.
ZhangXGuoXGaoQ, et al.Association between cigarette smoking history, metabolic phenotypes, and EGFR mutation status in patients with non-small cell lung cancer. J Thorac Dis2023; 15(10): 5689–5699.
38.
HolmeJAVondráčekJMachalaM, et al.Lung cancer associated with combustion particles and fine particulate matter (PM2. 5)-the roles of polycyclic aromatic hydrocarbons (PAHs) and the aryl hydrocarbon receptor (AhR). Biochem Pharmacol2023; 216: 115801.
39.
PinkaewDDammadTBitarM, et al.Tobacco, second-hand smoke and cancer, environmental oncology: Theory and impact2023: 119–148.
40.
JeffordCEIrminger-FingerI. Mechanisms of chromosome instability in cancers. Crit Rev Oncol Hematol2006; 59(1): 1–14.
41.
ChapmanAMSunKYRuestowP, et al.Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers. Lung Cancer2016; 102: 122–134.
42.
HoangPHLandiMT. DNA methylation in lung cancer: mechanisms and associations with histological subtypes, molecular alterations, and major epidemiological factors. Cancers2022; 14(4): 961.
43.
SharifniaT. Genetic and chemical modifiers of EGFR dependence in non-small cell lung cancer. Doctoral dissertation. Cambridge, MA: Harvard University, 2014.
44.
JacksonRC. Evolutionary dynamics of malignancy. Berlin: Springer, 2023.
